List of Excipients in Branded Drug GAVILYTE-N

« Back to Dashboard

Generic Drugs Containing GAVILYTE-N

Company	Ingredient	NDC	Excipient
Lupin PharmaceuticalsInc	polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate	43386-050	MALTODEXTRIN
Lupin PharmaceuticalsInc	polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate	43386-050	SACCHARIN SODIUM

What are the Most Frequently-Used Excipients in GAVILYTE-N?

# Of NDCs	Excipient
1	MALTODEXTRIN
1	SACCHARIN SODIUM

GaviLyte-N Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 28, 2026

GaviLyte-N is a polyethylene glycol 3350-electrolyte bowel-preparation product used before colonoscopy and other gastrointestinal procedures. Its commercial position depends less on active-ingredient exclusivity than on manufacturing cost, taste, reconstitution performance, packaging, pharmacy distribution, and institutional purchasing. The product contains no novel chemical entity and is generally exposed to generic competition. The strongest commercial opportunities are differentiated flavor systems, lower-volume regimens, improved powder handling, private-label supply, and procedure-center contracts.

What is GaviLyte-N and which ingredients define its formulation?

GaviLyte-N is an osmotic bowel-cleansing powder that is reconstituted with water before oral administration. The formulation is designed to produce an electrolyte-balanced lavage solution that limits net sodium and water absorption during rapid-volume gastrointestinal cleansing.

GaviLyte-N active and functional ingredients

The labeled contents per 4-liter solution are generally:

Component	Approximate quantity per 4 L	Functional role
Polyethylene glycol 3350	236 g	Osmotic agent; retains water in the intestinal lumen
Sodium sulfate	22.74 g	Electrolyte and osmotic contributor
Sodium bicarbonate	6.74 g	Buffer and electrolyte
Sodium chloride	5.86 g	Electrolyte replacement
Potassium chloride	2.97 g	Potassium replacement
Flavor component	Product-specific	Improves palatability
Water	Added by user	Reconstitution vehicle

The precise commercial label and package configuration should control for any current formulation assessment. GaviLyte-N is supplied as a powder for solution rather than as a ready-to-drink liquid, which reduces shipping weight and improves storage economics compared with a fully hydrated product (DailyMed, n.d.-a).

How does GaviLyte-N compare with GaviLyte-C?

GaviLyte-N and GaviLyte-C use closely related polyethylene glycol-electrolyte platforms. The principal formulation distinction is the electrolyte composition, particularly the presence or absence of sulfate-related components and the use of different buffering systems.

Attribute	GaviLyte-N	GaviLyte-C
Dosage form	Powder for oral solution	Powder for oral solution
Primary osmotic agent	PEG 3350	PEG 3350
Electrolyte system	Sodium sulfate, sodium chloride, potassium chloride, sodium bicarbonate	PEG-electrolyte system with a different salt profile
Reconstitution	Large-volume solution	Large-volume solution
Primary commercial differentiator	Cost, supply, tolerability, institutional contracting	Same categories
Regulatory pathway	Generic or abbreviated pathway positioning	Generic or abbreviated pathway positioning

The two products compete primarily on formulary preference, price, availability, patient acceptance, and physician familiarity. Neither product has a strong small-molecule exclusivity barrier.

What excipients are protected in GaviLyte-N?

GaviLyte-N has limited conventional excipient differentiation. The active osmotic and electrolyte ingredients perform most of the formulation work. The commercial excipient opportunity is concentrated in flavor, powder processing, stability, and packaging rather than in a proprietary therapeutic excipient.

Flavor and palatability excipients

Large-volume bowel preparations have a known adherence problem. Patients may reject the product because of volume, saltiness, sweetness, odor, or aftertaste. A supplier can create commercial value through:

• Citrus, lemon-lime, berry, or neutral flavor systems.
• Reduced bitterness and reduced metallic aftertaste.
• Flavor systems that remain stable after reconstitution.
• Flavors compatible with clear-liquid restrictions.
• Separate flavor packets that let patients select or omit flavor.
• Masking systems that do not materially increase sugar, sodium, or osmolality.

Flavor components are usually weak patent assets unless they are tied to a defined composition, concentration range, stability profile, or measurable palatability result. Trade-secret protection, supplier exclusivity, and formulation know-how may be more practical than a standalone patent.

Flow, dispersibility, and reconstitution aids

PEG 3350 and inorganic salts can create powder-blending and reconstitution challenges. A commercial manufacturer may improve:

• Powder flow through particle-size control.
• Blend uniformity across the container.
• Dissolution time.
• Reduction of clumping after humidity exposure.
• Uniform distribution of low-dose potassium chloride and bicarbonate.
• Reconstitution in cold water.
• Stability after the patient adds water.

Potential excipient tools include colloidal silicon dioxide, maltodextrin, processing aids, or controlled particle-size fractions. Each option must be evaluated against the final product's electrolyte composition, oral tolerability, regulatory status, and labeling requirements.

Packaging excipients and moisture protection

Moisture control is a central technical issue for a hygroscopic powder product. Suitable packaging strategies can include:

• High-barrier sachets.
• Foil-laminate pouches.
• Induction-sealed bottles.
• Desiccant-integrated containers.
• Unit-dose packaging for hospital or ambulatory surgery use.
• Tamper-evident closures.
• Packaging that reduces powder adhesion to the container wall.

Packaging innovations can be patentable when they solve a defined stability or dispensing problem. They can also be protected through manufacturing know-how and supplier agreements.

What patents protect GaviLyte-N?

Public product labeling does not establish a material patent barrier around the PEG 3350-electrolyte concept. The platform has been used for decades, and the relevant commercial products are generally exposed to abbreviated generic competition.

Patent and exclusivity assessment

Issue	GaviLyte-N assessment
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orphan-drug exclusivity	Not indicated
Core PEG-electrolyte composition	Mature technology with limited exclusivity value
Formulation patents	Possible for specific flavor, stability, packaging, or process claims
Method-of-use patents	Potentially narrow and difficult to enforce against routine bowel preparation
Orange Book-listed protection	No material patent barrier is established by the product label alone
Generic exposure	High
Biosimilar exposure	Not applicable

A full patent clearance review would need to search U.S. patents and applications assigned to the product sponsor, contract manufacturers, flavor suppliers, and competing PEG-electrolyte companies. Public labeling is not a substitute for a complete patent-family search.

When does GaviLyte-N lose exclusivity?

GaviLyte-N does not have the exclusivity profile of a newly approved innovative drug. Its commercial exposure is governed mainly by the availability of competing approved products and the ability of manufacturers to meet quality and supply requirements.

For a product approved through an ANDA, the principal commercial question is not the expiration of NCE exclusivity. It is whether another manufacturer can obtain approval for a therapeutically equivalent product and compete on price or supply. FDA approval of a generic bowel-preparation product can create immediate pricing pressure, subject to market access and manufacturing capacity (FDA, n.d.-a).

FDA regulatory status

GaviLyte-N is a prescription bowel-preparation product regulated as a drug. The relevant approval obligations include:

• Conformance with the applicable monograph or approved product specifications.
• Demonstration of pharmaceutical equivalence.
• Demonstration of bioequivalence where applicable.
• Compliance with current good manufacturing practice.
• Control of blend uniformity and content uniformity.
• Stability testing in the proposed container-closure system.
• Labeling for contraindications, warnings, electrolyte abnormalities, and administration instructions.

The product does not require a biosimilar pathway because PEG 3350 and the accompanying electrolytes are chemically defined ingredients rather than a biologic reference product.

What Orange Book status applies to GaviLyte-N?

The Orange Book is relevant to approved drug products, therapeutic equivalence ratings, reference-listed drugs, and patent or exclusivity information. For a mature generic bowel-preparation product, Orange Book exposure usually centers on the reference product and any listed patents associated with an approved product, not on a durable patent estate surrounding the underlying PEG-electrolyte concept (FDA, n.d.-b).

A prospective entrant should review:

1. The current reference-listed drug for the PEG-electrolyte product.
2. Any patents or exclusivity codes attached to the reference product.
3. Therapeutic-equivalence ratings for competing products.
4. Approved strengths, package sizes, and flavor configurations.
5. Any suitability petitions or product-specific FDA correspondence.
6. Manufacturing-site status and supply interruptions.

No Paragraph IV strategy should be inferred solely from a product name. The proposed ANDA must be evaluated against the current reference product, listed patents, labeling requirements, and any relevant regulatory exclusivity.

Which companies are challenging or competing with GaviLyte-N?

Competition comes from several product categories rather than one direct generic substitute.

Direct PEG-electrolyte competitors

Direct competitors include:

• GoLYTELY and equivalent PEG-electrolyte solutions.
• GaviLyte-C and related products.
• NuLYTELY-type formulations.
• Other FDA-approved polyethylene glycol-electrolyte preparations.

Lower-volume bowel-preparation competitors

Lower-volume products can compete more effectively on patient convenience. These include sodium sulfate-based preparations, picosulfate-based products, and other concentrated regimens. They may command higher prices when physicians and procedure centers value improved patient acceptance.

Over-the-counter and nonprescription alternatives

MiraLAX-based regimens and magnesium-containing preparations can compete in selected clinical protocols. Their use depends on physician preference, patient risk factors, institutional protocols, and the procedure's cleansing requirements.

What formulation patents could create commercial value?

The strongest patent opportunities are incremental and product-specific.

Potential patentable areas

Innovation area	Commercial value	Patent strength
Improved flavor system	Higher completion rates and patient satisfaction	Moderate if composition and data are specific
Reduced-volume formulation	Convenience and potential premium pricing	High if technically enabled and clinically validated
Rapid-dissolving powder	Better patient experience and lower preparation friction	Moderate
Humidity-resistant granules	Improved shelf life and manufacturing yield	Moderate to high
Unit-dose packaging	Hospital and procedure-center efficiency	Moderate
Stability after reconstitution	Longer usable period after mixing	Moderate
Electrolyte-balanced concentrated solution	Reduced shipping and administration burden	Potentially high, but technically difficult
Combination regimen with adjunctive stimulant	Differentiated bowel-cleansing protocol	Depends on clinical evidence and prior art

A formulation patent should claim measurable technical advantages rather than generic use of a known excipient. Useful claim parameters may include dissolution time, residual moisture, particle-size distribution, osmolality, stability period, flavor intensity, and patient completion rate.

What generic entry risks exist for GaviLyte-N?

Generic entry risk is high because the product uses mature ingredients and a conventional oral-solution dosage form. The main barriers are operational rather than fundamental patent barriers.

Key entry barriers

• Consistent sourcing of pharmaceutical-grade PEG 3350.
• Control of electrolyte blend uniformity.
• Moisture protection during manufacturing and distribution.
• Reproducible flavor quality.
• Validation of the container-closure system.
• FDA inspection readiness.
• Reliable supply to wholesalers and institutional accounts.
• Ability to compete against established contract manufacturers.

A new entrant can still face meaningful execution risk. A failed stability package, inaccurate electrolyte content, poor dissolution, or packaging failure can delay approval or trigger recalls.

Paragraph IV challenges

A Paragraph IV certification may be relevant if an ANDA references a listed drug with unexpired patents. In a mature PEG-electrolyte category, the expected value of a Paragraph IV challenge depends on whether any listed patent covers a meaningful product feature. A weak formulation patent may not justify litigation expense if the entrant can design around it.

The principal launch scenarios are:

Scenario	Likely effect
No relevant unexpired patent	Launch after approval and applicable regulatory requirements
Narrow formulation patent	Design-around or litigation
Broad listed patent with commercial relevance	Paragraph IV litigation risk
Supply shortage at incumbent	Faster formulary adoption for a new entrant
Hospital contract win	Rapid share capture despite low retail visibility
Premium lower-volume substitute	Limited direct price competition

How strong is the GaviLyte-N patent estate?

The estate is best characterized as weak for core composition protection and potentially moderate for narrow formulation or process improvements. The principal ingredients are well-established. A defensible patent position would need to rely on a specific technical improvement supported by comparative data.

Strength assessment

Patent category	Estimated strategic strength
PEG 3350 and electrolyte composition	Low
General bowel-cleansing method	Low
Specific flavor composition	Low to moderate
Moisture-resistant powder process	Moderate
Reconstitution and stability system	Moderate
Reduced-volume concentrated formulation	Moderate to high if clinically viable
Packaging and dispensing system	Moderate
Manufacturing process with validated quality advantage	Moderate

The most durable protection may be a layered package consisting of formulation patents, process patents, trade secrets, supplier exclusivity, trademark rights, and institutional contracts.

What licensing deals could support GaviLyte-N growth?

Licensing opportunities are more likely to involve manufacturing and commercial rights than molecule ownership.

Attractive licensing targets

• Regional rights for approved PEG-electrolyte products.
• Private-label supply for pharmacy chains.
• Co-development of flavored or lower-volume formulations.
• Contract manufacturing with validated powder-blending capacity.
• Exclusive flavor-system supply.
• Hospital and ambulatory surgery distribution agreements.
• Packaging technology licenses for moisture-resistant unit doses.
• International registrations based on an existing U.S. dossier.

A licensee should prioritize rights that reduce time to market or lower manufacturing risk. A flavor license alone is unlikely to justify substantial royalties unless it is linked to clinical tolerability data or a protected delivery format.

What is the revenue opportunity for GaviLyte-N?

GaviLyte-N is a volume-driven product. Revenue depends on procedure volume, payer mix, contract pricing, pharmacy distribution, and the share of colonoscopy patients receiving a PEG-electrolyte preparation.

The principal commercial models are:

1. Low-cost generic supply through wholesalers.
2. Private-label manufacturing for pharmacies.
3. Institutional contracts with hospitals and ambulatory surgery centers.
4. Premium packaging or flavor differentiation.
5. International licensing.
6. Portfolio bundling with other gastrointestinal products.

Institutional accounts can be more attractive than retail sales because a single contract may cover large procedure volumes. The tradeoff is greater price pressure and strict supply-performance requirements.

Key Takeaways

• GaviLyte-N is a mature PEG 3350-electrolyte bowel-preparation product.
• Its core composition has limited exclusivity value because the ingredients and therapeutic use are established.
• Biosimilar risk is irrelevant; generic and therapeutic-equivalent competition are the relevant risks.
• The strongest commercial opportunities are flavor, reconstitution, moisture protection, packaging, lower volume, and supply reliability.
• A new patent estate should focus on measurable formulation or manufacturing improvements.
• Paragraph IV exposure depends on current Orange Book listings for the applicable reference product, not on the GaviLyte-N brand name alone.
• Licensing opportunities are strongest in private-label supply, regional distribution, contract manufacturing, flavor technology, and institutional purchasing.
• Manufacturing execution and distribution contracts are likely to matter more than core composition patents.

FAQs

Is GaviLyte-N a biologic that can face biosimilar competition?

No. GaviLyte-N contains chemically defined ingredients and is subject to conventional drug approval and generic competition rather than the biosimilar pathway.

Can a new company patent a PEG 3350 bowel-preparation product?

A broad patent on PEG 3350 bowel preparation would face substantial prior-art risk. A narrower patent may be available for a defined flavor system, concentrated formulation, packaging configuration, stability improvement, or manufacturing process supported by comparative data.

Does GaviLyte-N have a strong Orange Book patent barrier?

The product category does not present an apparent strong core-composition barrier. A current Orange Book and patent-family review is required to determine whether a specific reference product has enforceable listed patents affecting an ANDA.

What excipient has the greatest commercial value in GaviLyte-N?

Flavor and taste-masking systems have the clearest patient-facing value. Moisture-control and processing aids may produce greater manufacturing value by improving stability, blend uniformity, and yield.

Is a lower-volume GaviLyte-N product commercially attractive?

Yes, if the formulation can preserve cleansing efficacy, electrolyte control, stability, and acceptable tolerability. Lower volume is commercially attractive because it addresses a primary limitation of large-volume bowel preparations, but it requires substantial formulation and clinical validation.

References

1. DailyMed. (n.d.-a). GaviLyte-N: Polyethylene glycol 3350, sodium chloride, sodium bicarbonate, and potassium chloride powder for solution. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.-a). Abbreviated new drug application ANDA process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.-c). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts